Shanghai ZJ Bio-Tech Co

Shanghai ZJ Bio-Tech Co Equity

The The Equity of Shanghai ZJ Bio-Tech Co (688317.SS) as of Oct 27, 2026 is 3.35 B CNY. In the previous year, The Equity was 3.64 B CNY — a change of -7.92% (lower).

Equity

3.35 BCNY

YoY

-7.92%

Last updated:

In 2025, Shanghai ZJ Bio-Tech Co's equity was 3.35 B CNY, a -7.92% increase from the 3.64 B CNY equity in the previous year.

The Shanghai ZJ Bio-Tech Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
532.66 M CNY
Jan 1, 2019
571.84 M CNY
Jan 1, 2020
1.46 B CNY
Jan 1, 2021
3.83 B CNY
Jan 1, 2022
4.20 B CNY
Jan 1, 2023
3.82 B CNY
Jan 1, 2024
3.64 B CNY
Jan 1, 2025
3.35 B CNY
The Shanghai ZJ Bio-Tech Co Equity history
YEAREquityYoY
3.35 BCNY-7.92%
3.64 BCNY-4.92%
3.82 BCNY-8.94%
4.20 BCNY+9.75%
3.83 BCNY+161.69%
1.46 BCNY+155.77%
571.84 MCNY+7.36%
532.66 MCNY+12.69%
472.70 MCNY-2.29%
483.76 MCNY+40.91%
343.31 MCNY+211.58%
110.18 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai ZJ Bio-Tech Co Stock analysis

What does Shanghai ZJ Bio-Tech Co do? Shanghai ZJ Bio-Tech Co., Ltd. generates revenue through the research, development, production, and sale of molecular diagnostic reagents and instruments. The company's primary products are nucleic acid detection kits and molecular diagnostic instruments, which are sold to customers in sectors including emergency public health safety, medical clinical diagnosis, entry-exit inspection and quarantine, and food safety. The firm focuses its business activities within the domestic market, targeting institutions and organizations requiring diagnostic solutions for public health and clinical applications. The company's business model centers on providing diagnostic reagents and equipment for critical applications such as emergency public health safety and medical clinical diagnosis. Its products are designed to meet the needs of domestic customers in healthcare, public safety, and food safety sectors, with a strong emphasis on molecular diagnostics. Shanghai ZJ Bio-Tech leverages its domestic market presence to serve institutions requiring reliable diagnostic tools for health and safety monitoring. Shanghai ZJ Bio-Tech Co., Ltd. operates with a domestic market focus, selling its molecular diagnostic instruments and reagents to entities involved in public health, clinical diagnosis, and food safety. The firm's revenue streams are derived from the sale of nucleic acid detection kits and molecular diagnostic instruments, which are essential for applications in emergency public health safety, medical clinical diagnosis, entry-exit inspection and quarantine, and food safety. Shanghai ZJ Bio-Tech Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Shanghai ZJ Bio-Tech Co's Equity

Shanghai ZJ Bio-Tech Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Shanghai ZJ Bio-Tech Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Shanghai ZJ Bio-Tech Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Shanghai ZJ Bio-Tech Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Shanghai ZJ Bio-Tech Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Shanghai ZJ Bio-Tech Co stock

The Equity of Shanghai ZJ Bio-Tech Co is 3.35 B CNY in 2025.

The Equity of Shanghai ZJ Bio-Tech Co changed from 3.64 B CNY to 3.35 B CNY, representing a -7.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Shanghai ZJ Bio-Tech Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Shanghai ZJ Bio-Tech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Shanghai ZJ Bio-Tech Co

All Key Metrics — Shanghai ZJ Bio-Tech Co